Study explores how anxiety affects prostate cancer treatment decisions
NCT ID NCT01877070
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study looks at how men with low-risk prostate cancer and their partners or close allies decide on treatment. Researchers want to understand how anxiety and uncertainty influence these choices. About 541 participants will fill out questionnaires about their feelings and preferences. The goal is to learn more about the decision-making process, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 541 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
Jun 2013
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants will be recruited from outpatient clinics at both the Urology Service at Memorial Sloan-Kettering Cancer Center (MSKCC). Patients may also be contacted by e-mail (securely using MSKSecure) or by mail.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: For patients: * Men who meet the NCCN guidelines for low risk prostate cancer, which include all of the following: * Most recent Gleason score ≤ 6, or clinical stage T1a or less; * Most recent PSA level below 10; * In the most recent biopsy, had fewer than 3 positive biopsy cores (with ≤ 50% cancer in each); OR the patient's doctor discussed active surveillance as a treatment option (as documented in visit notes of the patient's medical record) * Are able to speak, read, write and understand English well enough to provide informed consent and complete study tasks * Has not made a treatment decision prior to consent, as per self report * 18 years of age or older For partners/close allies: * Considered a partner/close ally to the patient in the treatment making decision, as reported by the patient * Are able to speak, read, write and understand English well enough to provide informed consent and complete study tasks * 18 years old or older Exclusion Criteria: For patients: * History of a cancer other than prostate cancer and non-melanoma skin cancer * Significant psychiatric or cognitive disturbance sufficient, in the investigator's judgment, to preclude providing informed consent or participating in the study activities (i.e., acute psychiatric symptoms which require individual treatment) For partners/close allies: * Significant psychiatric or cognitive disturbance sufficient, in the investigator's judgment, to preclude providing informed consent or participating in the study activities (i.e., acute psychiatric symptoms which require individual treatment)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Low risk prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.